entertainment -WSS

entertainment

author：knowledge 2025-09-28 22:28:15 - browse：878

MODERNA - Norwood facility — Alex Hogan/STAT

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses.

The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.

“We’re excited to move forward in our discussions with regulators, and hopefully continue to help address respiratory viruses globally,” Moderna President Stephen Hoge told STAT in an interview in which he acknowledged that the fall 2025 vaccine rollout is a target the company would like to hit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： California wildfire smoke linked to 52,000 early deaths, study says

WSS

Questions and answers about ramping up H5N1 bird flu vaccine

Questions and answers about ramping up H5N1 bird flu vaccine

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

At flashy new research hub, AstraZeneca lays out ambitious growth goals

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Dobbs anniversary: the lost opportunity of abortion as health care

New report analyzes digital physical therapy solutions' effectiveness

Activists slam private health insurers over coverage restrictions

Cue Health, Covid

The cancer drug shortage isn’t new — and neither are the solutions

As a primary care physician, here's how I hope to partner with AI

DIEP, the 'gold standard' of breast reconstruction, is under threat

ASCO eve: Let’s set the table for this year's meeting

Peter Hotez and the public health issue of online harassment

ASCO eve: Let’s set the table for this year's meeting

hotspot

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

For longer

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Report captures long Covid’s disabling effects and policy challenges

hotspot

focus

leisure time

entertainment